This molecular diagnostic tool helps to identify individuals at elevated risk for early heart attack. As part of the agreement, the test will be marketed by Labec Pharma and the tests will be processed at Interleukin Genetics’s Clinical Laboratory Improvement Amendments-certified laboratory in Waltham, Massachusetts.
Interleukin Genetics will receive royalties and commercial milestone payments. The Interleukin Genetics’s heart health test is currently marketed within the US under the brand name Gensona.
Lewis Bender, CEO of Interleukin Genetics, said: “We are excited about this partnership with Labec Pharma, which will allow for broader and international distribution of this important genetic test product. Our heart health genetic test can give a better understanding of a person’s overall risk for heart attack, so that individuals and their physicians can begin to take the steps necessary for lowering risk to improve health outcomes.”